光化学洗脱市场报告：趋势、预测和竞争分析（至 2031 年）

预计全球光交换疗法市场在2025年至2031年间的复合年增长率将达到5.7%，其中阻塞性细支气管炎和復发性急性排斥市场将迎来发展机会。预计全球光交换疗法市场在2025年至2031年间的复合年增长率将达到5.7%。该市场的主要驱动因素包括自体免疫疾病盛行率的上升、移植物抗宿主疾病病例的增加以及对非侵入性治疗方案的需求。

Lucintel 预测体外光化学疗法将在预测期内达到最高成长。

根据应用，復发性急性排斥预计将出现高成长。

根据地区，预计亚太地区将在预测期内实现最高成长。

这份超过150页的综合报告将为您提供宝贵的见解，协助您的业务决策。以下是一些范例资料和见解：

光化学疗法市场的新趋势

光化学疗法市场正在经历深刻的变革时期，其主要趋势由技术创新、不断增长的患者需求和不断发展的医疗保健系统所推动，有助于重塑全球治疗性光化学疗法的格局。

• 光交换疗法设备的技术进步：更紧凑、自动化且患者友好的光交换疗法设备的开发正在改善治疗效果。这些进步缩短了治疗时间，提高了安全性，并改善了患者的整体体验。随着科技的不断发展，光交换疗法有望变得更加便捷和有效率。
• 癌症和自体免疫疾病的治疗应用日益广泛：光化学疗法正逐渐被认可为治疗胆管细胞淋巴瘤（CTCL）等癌症和移植物抗宿主疾病（GVHD）等自体免疫疾病的有效治疗方法。这一趋势促使全球各地的医院和诊所越来越多地采用光化学疗法，从而改善患者的治疗效果并促进市场成长。
• 着重于个人化治疗方案：随着个人化医疗的兴起，光交换疗法正日益根据个别患者的需求进行客製化，尤其是在癌症治疗领域。这一趋势致力于提高光交换疗法的精准度和疗效，确保其根据每位患者的独特病情和治疗需求进行量身定制。
• 转向门诊光化学疗法：医院和诊所越来越多地在门诊提供光化学疗法，为患者提供更便捷的治疗。这种转变得益于光化学疗法设备的技术进步，这些设备能够提高治疗效率，减少住院时间和相关费用，并提高患者满意度。
• 拓展新兴市场：由于对先进医疗治疗的需求不断增长，光化学疗法市场正在向新兴经济体扩张。印度和中国等国家越来越多地采用光化学疗法治疗慢性疾病，为这些地区的市场创造了巨大的成长机会。

这些新兴趋势正在推动技术进步、可及性和治疗精准度的提高，从而重塑光化学疗法市场。随着市场的成长，对个人化、高效和门诊病人友善的光化学疗法选项的需求预计将会增加，尤其是在新兴经济体中，这将促进全球市场的显着成长。

光化学洗脱市场的最新趋势

光化学疗法市场近期呈现出显着趋势，技术、临床应用和患者照护方面均取得了显着进展。这些发展推动了光化学疗法日益成为各种疾病的有效治疗方法，尤其是在癌症和自体免疫疾病的治疗方面。

• 美国食品药物管理局 (FDA)核准新型光化学疗法系统美国食品药物管理局 (FDA) 近期核准了新型光化学疗法设备，该设备安全性更高，处理效率更高。这些核准将促进光化学疗法的广泛应用，尤其是在血癌和自体免疫疾病的治疗领域，从而进一步扩大市场。
• 光化学疗法研究的新兴伙伴关係关係：我们注意到，学术机构与医疗保健公司之间正在建立越来越多的策略联盟，以推进光化学疗法研究。这些合作致力于开发更有效、更精准的疗法，加速将光化学疗法融入标准治疗方法。
• 光化学疗法在固体癌治疗中的应用进展：光化学疗法正应用于固体癌的治疗，这与它传统的治疗血癌的应用相比，是一个重大转变。早期临床试验已显示出良好的效果，这可能将光化学疗法的应用范围拓展到更广泛的癌症治疗领域。
• 门诊光化学疗法的发展：随着科技的进步，门诊光化学疗法正变得越来越普遍。可携式高效设备的开发使患者能够在门诊接受治疗，从而提高了便利性并降低了医疗成本。这一趋势预计将推动光化学疗法在全球的普及。
• 光化学疗法参与者正在国际上扩张：几家领先的光化学疗法设备製造商正在扩大市场影响，尤其是在亚洲和拉丁美洲。随着这些地区医疗保健体系的发展，对包括光化学疗法在内的先进疗法的需求不断增长，这推动了这些地区的市场成长。

光化学疗法市场近期的趋势是，其应用范围和有效性不断提升，尤其是在技术进步、临床研究和更广泛的可及性方面。这些变化使光化学疗法成为肿瘤学和自体免疫疾病治疗的重要选择，并促进了市场的持续成长和创新。

目录

第一章执行摘要

第二章全球光化学疗法市场：市场动态

• 简介、背景和分类
• 供应链
• 产业驱动力与挑战

第三章市场趋势与预测分析（2019-2031）

• 宏观经济趋势（2019-2024）及预测（2025-2031）
• 全球光分离市场趋势（2019-2024 年）及预测（2025-2031 年）
• 全球光化学疗法市场（按类型）
  • 体外光分离疗法
  • 白血球分离术
  • 血浆置换
  • 其他的
• 全球光化学疗法市场（按应用）
  • 阻塞性细支气管炎症候群
  • 復发性急性排斥反应
  • 其他的

第四章。各地区市场趋势及预测分析（2019-2031）

• 全球光化学疗法市场（按地区）
• 北美光化学疗法市场
• 欧洲光化学疗法市场
• 亚太光化学疗法市场
• 世界其他地区的光化学洗脱市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 全球光化学疗法市场成长机会（按类型）
  • 全球光化学洗脱市场的成长机会（按应用）
  • 全球光分离市场各区域成长机会
• 全球光化学疗法市场的新趋势
• 战略分析
  • 新产品开发
  • 全球光化学疗法市场容量不断扩大
  • 全球光化学洗脱市场中的合併、收购与合资企业
  • 认证和许可

第七章主要企业简介

• Haemonetics
• Fresenius Kabi
• Terumo
• Macopharma
• Mallinckrodt Pharmaceuticals

The future of the global photopheresis market looks promising with opportunities in the bronchiolitis obliterans syndrome and recurrent acute rejection markets. The global photopheresis market is expected to grow with a CAGR of 5.7% from 2025 to 2031. The major drivers for this market are the rising prevalence of autoimmune disease, increasing cases of graft-versus-host disease, and demand for non-invasive treatment options.

Lucintel forecasts that, within the type category, extracorporeal photopheresis is expected to witness the highest growth over the forecast period.

Within the application category, recurrent acute rejection is expected to witness higher growth.

In terms of region, APAC is expected to witness the highest growth over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Photopheresis Market

The photopheresis market is undergoing significant transformation, with key trends emerging due to innovations in technology, increasing patient demand, and evolving healthcare systems. These trends are helping to reshape the landscape of photopheresis treatment across the world.

• Technological Advancements in Photopheresis Devices: The development of more compact, automated, and patient-friendly photopheresis devices is improving treatment outcomes. These advancements reduce treatment times, increase safety, and enhance the overall patient experience. As the technology continues to evolve, it is expected to make photopheresis more accessible and efficient.
• Growing Adoption for Cancer and Autoimmune Diseases: Photopheresis is being increasingly recognized as an effective treatment for cancers like CTCL and autoimmune diseases such as GVHD. This trend is leading to greater adoption of photopheresis therapies in hospitals and clinics worldwide, improving patient outcomes and expanding market growth.
• Focus on Personalized Treatment Options: With personalized medicine on the rise, photopheresis is being tailored to individual patient needs, particularly in cancer care. This trend focuses on enhancing the precision and efficacy of photopheresis treatments, ensuring that they are suited to each patient's unique condition and treatment requirements.
• Shift toward Outpatient Photopheresis Procedures: Hospitals and clinics are increasingly offering outpatient photopheresis treatments, making it more convenient for patients. This shift is driven by technological advancements in photopheresis devices that enable more efficient treatments, reducing hospital stays and associated costs, and improving patient satisfaction.
• Expansion into Emerging Markets: The photopheresis market is expanding into emerging economies, where there is a growing demand for advanced medical treatments. Countries such as India and China are seeing increased adoption of photopheresis for treating chronic diseases, presenting a significant growth opportunity for the market in these regions.

These emerging trends are reshaping the photopheresis market by driving technological advancements, improving accessibility, and enhancing the precision of treatments. As the market grows, particularly in emerging economies, the demand for personalized, efficient, and outpatient-friendly photopheresis options is expected to increase, contributing to significant growth in the global market.

Recent Developments in the Photopheresis Market

The photopheresis market has seen notable developments in recent years, with significant advancements in technology, clinical applications, and patient care. These developments have contributed to the growing adoption of photopheresis as an effective treatment for a variety of conditions, particularly in the treatment of cancer and autoimmune diseases.

• FDA Approval of New Photopheresis Systems: The U.S. FDA has recently approved new photopheresis devices that offer improved safety features and more efficient processing. These approvals are driving the widespread adoption of photopheresis, particularly in the treatment of blood cancers and autoimmune conditions, which is expanding the market further.
• Emerging Partnerships for Photopheresis Research: There has been an increase in strategic partnerships between academic institutions and healthcare companies to advance photopheresis research. These collaborations are focused on developing more effective and precise treatments, helping to accelerate the integration of photopheresis into standard treatment regimens.
• Development of Photopheresis for Solid Tumors: Photopheresis is being explored for the treatment of solid tumors, a significant shift from its traditional use in blood cancers. Early-stage clinical trials have shown promising results, potentially expanding the use of photopheresis to a broader range of cancer treatments.
• Growth of Photopheresis in Outpatient Clinics: Outpatient photopheresis treatments are becoming more common as technology improves. With the development of more portable and efficient devices, patients can undergo treatment in outpatient settings, improving convenience and reducing healthcare costs. This trend is expected to drive the adoption of photopheresis therapy worldwide.
• International Expansion of Photopheresis Providers: Several leading photopheresis device manufacturers are expanding their market presence in international markets, particularly in Asia and Latin America. As healthcare systems in these regions evolve, there is increased demand for advanced treatments, including photopheresis, which is driving market growth in these areas.

Recent developments in the photopheresis market are enhancing its adoption and effectiveness, particularly through technological advancements, clinical research, and broader accessibility. These changes are positioning photopheresis as a vital treatment option in oncology and autoimmune disease care, contributing to the market's ongoing growth and innovation.

Strategic Growth Opportunities in the Photopheresis Market

The photopheresis market offers several growth opportunities across key applications, particularly in the treatment of cancers, autoimmune disorders, and other chronic conditions. As technology improves and adoption increases, new markets and applications are emerging, offering significant growth potential.

• Cancer Treatment Applications: Photopheresis is increasingly being adopted in the treatment of cancers, especially cutaneous T-cell lymphoma and graft-versus-host disease. The continued development of photopheresis technologies for cancer therapies presents a key growth opportunity, expanding treatment options for patients and increasing market demand.
• Autoimmune Disorder Treatment: Photopheresis has proven effective in treating autoimmune disorders like GVHD and scleroderma. As awareness of its efficacy grows, there is significant potential for expanded use in autoimmune disease management, particularly in regions with high prevalence, such as North America and Europe.
• Pediatric Applications: Photopheresis is gaining traction in pediatric applications for treating autoimmune diseases and certain cancers. As treatment regimens become more personalized and less invasive, photopheresis holds promise in offering children more manageable treatment options with fewer side effects.
• Outpatient Treatment Opportunities: As photopheresis devices become more compact and efficient, the potential for outpatient treatments increases. This development offers a strategic growth opportunity, allowing healthcare providers to offer more flexible and cost-effective treatment options for patients, improving patient satisfaction, and expanding market reach.
• Expanding Markets in Developing Regions: Emerging markets, such as India and China, are increasingly adopting advanced medical technologies like photopheresis. The growing healthcare infrastructure in these regions presents significant growth opportunities for photopheresis providers looking to expand their market presence and serve a growing patient base.

The photopheresis market is poised for substantial growth due to key strategic opportunities in cancer treatment, autoimmune disorders, and pediatric care. As technology advances and accessibility increases, particularly in outpatient settings and emerging markets, these growth areas will drive the market's expansion and enhance its role in global healthcare.

Photopheresis Market Driver and Challenges

The photopheresis market is influenced by various technological, economic, and regulatory drivers and challenges. These factors are shaping the growth of the market by influencing the adoption of photopheresis technology, its effectiveness, and its accessibility across different regions.

The factors responsible for driving the photopheresis market include:

1. Technological Advancements in Photopheresis Devices: The continuous development of more compact, efficient, and automated photopheresis devices is a major driver in the market. These advancements improve patient comfort, reduce treatment times, and increase the overall efficiency of photopheresis therapies, driving greater adoption in clinical settings.

2. Rising Incidence of Autoimmune Diseases and Cancers: An increase in the incidence of autoimmune diseases and cancers, especially hematologic malignancies, is driving the demand for photopheresis treatments. As these conditions become more prevalent, the need for effective treatment options like photopheresis grows, contributing to market expansion.

3. Government Support and Reimbursement Policies: Government initiatives and favorable reimbursement policies are encouraging healthcare providers to adopt photopheresis treatments. This support, especially in developed markets, ensures that photopheresis becomes more accessible to patients, fueling its market growth.

4. Growing Patient Preference for Non-invasive Treatments: Patients increasingly prefer non-invasive treatments like photopheresis over traditional methods such as chemotherapy or surgery. The rising demand for less invasive treatment options is a significant driver for photopheresis adoption, particularly for chronic conditions like autoimmune diseases.

5. Expanding Healthcare Infrastructure in Emerging Markets: Improving healthcare infrastructure in developing regions is opening new opportunities for photopheresis treatment. As hospitals and clinics in these regions invest in advanced technologies, the demand for photopheresis is expected to increase, contributing to market growth.

Challenges in the photopheresis market are:

1. High Treatment Costs: The high cost of photopheresis treatments, including the expense of devices and specialized procedures, remains a significant challenge. These costs can limit the adoption of photopheresis in lower-income regions and may hinder broader market expansion.

2. Efficacy Concerns and Limited Indications: Despite its effectiveness in certain conditions, the efficacy of photopheresis in treating other diseases is still being studied. Limited indications for use in non-cancerous conditions may slow the growth of the market, as more evidence is needed to justify its broader application.

3. Regulatory Hurdles and Approval Delays: The regulatory approval process for new photopheresis devices can be lengthy and complex, delaying market entry. Stringent regulations in different regions may slow the adoption of new technologies, which can impact market growth and innovation.

The major drivers of the photopheresis market include technological advancements, rising disease prevalence, and supportive government policies. However, challenges such as high treatment costs, limited indications, and regulatory hurdles must be overcome for the market to reach its full potential. Addressing these challenges will be key to sustaining growth in the photopheresis market.

List of Photopheresis Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies photopheresis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the photopheresis companies profiled in this report include-

• Haemonetics
• Fresenius Kabi
• Terumo
• Macopharma
• Mallinckrodt Pharmaceuticals

Photopheresis Market by Segment

The study includes a forecast for the global photopheresis market by type, application, and region.

Photopheresis Market by Type [Value from 2019 to 2031]:

• Extracorporeal Photopheresis
• Leukapheresis
• Plasmapheresis
• Others

Photopheresis Market by Application [Value from 2019 to 2031]:

• Bronchiolitis Obliterans Syndrome
• Recurrent Acute Rejection
• Others

Photopheresis Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Photopheresis Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. It highlights recent developments by major photopheresis producers in key regions: the USA, China, India, Japan, and Germany.

• United States: In the U.S., photopheresis technology is increasingly being used for treating conditions like cutaneous T-cell lymphoma (CTCL) and graft-versus-host disease (GVHD). Key players in the market are focusing on improving the efficiency and safety of photopheresis machines, as well as enhancing patient comfort during treatment.
• China: China is witnessing a surge in demand for photopheresis treatments, particularly for cancer and autoimmune diseases. The government's focus on improving healthcare infrastructure is driving the adoption of photopheresis technologies, and local manufacturers are increasingly involved in the production of photopheresis devices to meet the rising demand.
• Germany: Germany remains at the forefront of photopheresis technology in Europe. Research institutions in the country are developing more advanced systems for photopheresis, particularly targeting hematologic malignancies. The German healthcare system continues to support the integration of photopheresis as a treatment for various blood disorders, pushing forward innovation in the market.
• India: India is seeing rapid adoption of photopheresis in the treatment of conditions like skin diseases and certain types of cancers. Indian hospitals are increasingly investing in photopheresis devices, driven by a growing demand for advanced cancer and autoimmune treatments. This development is enhancing the treatment landscape in the country.
• Japan: In Japan, photopheresis is gaining popularity for treating conditions such as lymphoma and autoimmune disorders. Japan's focus on advancing medical technologies is boosting the market, with local companies developing innovative photopheresis systems that emphasize patient comfort, treatment efficiency, and safety.

Features of the Global Photopheresis Market

Market Size Estimates: Photopheresis market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Photopheresis market size by type, application, and region in terms of value ($B).

Regional Analysis: Photopheresis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the photopheresis market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the photopheresis market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the photopheresis market by type (extracorporeal photopheresis, leukapheresis, plasmapheresis, and others), application (bronchiolitis obliterans syndrome, recurrent acute rejection, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Photopheresis Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Photopheresis Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Photopheresis Market by Type
  • 3.3.1: Extracorporeal Photopheresis
  • 3.3.2: Leukapheresis
  • 3.3.3: Plasmapheresis
  • 3.3.4: Others
• 3.4: Global Photopheresis Market by Application
  • 3.4.1: Bronchiolitis Obliterans Syndrome
  • 3.4.2: Recurrent Acute Rejection
  • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Photopheresis Market by Region
• 4.2: North American Photopheresis Market
  • 4.2.1: North American Market by Type: Extracorporeal Photopheresis, Leukapheresis, Plasmapheresis , and Others
  • 4.2.2: North American Market by Application: Bronchiolitis Obliterans Syndrome, Recurrent Acute Rejection, and Others
• 4.3: European Photopheresis Market
  • 4.3.1: European Market by Type: Extracorporeal Photopheresis, Leukapheresis, Plasmapheresis , and Others
  • 4.3.2: European Market by Application: Bronchiolitis Obliterans Syndrome, Recurrent Acute Rejection, and Others
• 4.4: APAC Photopheresis Market
  • 4.4.1: APAC Market by Type: Extracorporeal Photopheresis, Leukapheresis, Plasmapheresis , and Others
  • 4.4.2: APAC Market by Application: Bronchiolitis Obliterans Syndrome, Recurrent Acute Rejection, and Others
• 4.5: ROW Photopheresis Market
  • 4.5.1: ROW Market by Type: Extracorporeal Photopheresis, Leukapheresis, Plasmapheresis , and Others
  • 4.5.2: ROW Market by Application: Bronchiolitis Obliterans Syndrome, Recurrent Acute Rejection, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Photopheresis Market by Type
  • 6.1.2: Growth Opportunities for the Global Photopheresis Market by Application
  • 6.1.3: Growth Opportunities for the Global Photopheresis Market by Region
• 6.2: Emerging Trends in the Global Photopheresis Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Photopheresis Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Photopheresis Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Haemonetics
• 7.2: Fresenius Kabi
• 7.3: Terumo
• 7.4: Macopharma
• 7.5: Mallinckrodt Pharmaceuticals